GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Callitas Health Inc (OTCPK:MPHMF) » Definitions » EV-to-EBITDA

Callitas Health (Callitas Health) EV-to-EBITDA : 0.00 (As of May. 18, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Callitas Health EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Callitas Health's enterprise value is $0.00 Mil. Callitas Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 was $-0.47 Mil. Therefore, Callitas Health's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Callitas Health's EV-to-EBITDA or its related term are showing as below:

MPHMF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 10.28
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-18), Callitas Health's stock price is $1.0E-6. Callitas Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $-0.020. Therefore, Callitas Health's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Callitas Health EV-to-EBITDA Historical Data

The historical data trend for Callitas Health's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Callitas Health EV-to-EBITDA Chart

Callitas Health Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.60 -2.71 -1.13 -0.94 -3.64

Callitas Health Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 -3.64 -8.48 -8.96 -9.58

Competitive Comparison of Callitas Health's EV-to-EBITDA

For the Biotechnology subindustry, Callitas Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Callitas Health's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Callitas Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Callitas Health's EV-to-EBITDA falls into.



Callitas Health EV-to-EBITDA Calculation

Callitas Health's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-0.472
=0.00

Callitas Health's current Enterprise Value is $0.00 Mil.
Callitas Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Callitas Health  (OTCPK:MPHMF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Callitas Health's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.0E-6/-0.020
=At Loss

Callitas Health's share price for today is $1.0E-6.
Callitas Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.020.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Callitas Health EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Callitas Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Callitas Health (Callitas Health) Business Description

Traded in Other Exchanges
N/A
Address
734 - 1055 Dunsmuir Street, Vancouver, BC, CAN, V7X 1B1
Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.